TRIM16 and hepatocellular carcinoma: Mechanically, TRIM16 could promote NFKBIZ ubiquitination to exacerbate HCC progression, which may be the underlying mechanism of the occurrence of sorafenib insensitivity in HCC clinical treatment (Fig. 8F).